Congenital myasthenic syndrome (CMS): drug treatment
Evidence-based neurology checklist on congenital myasthenic syndrome (cms): drug treatment: Pyridostigmine: indications ChAT Sodium channel Fast channel Rapsyn Pyridostigmine: contraindications 3,4 diaminopyridine (3,4 DAP): indications 3,4 diaminopyridine (3,4 DAP): contraindications Treatment of…
Pyridostigmine: indications
- ChAT
- Sodium channel
- Fast channel
- Rapsyn
Pyridostigmine: contraindications
3,4 diaminopyridine (3,4 DAP): indications
3,4 diaminopyridine (3,4 DAP): contraindications
Treatment of slow channel
Treatment of DOK7
References
- Spillane J, Beeson DJ, Kullmann DM. Myasthenia and related disorders of the neuromuscular junction. JNNP 2010; 81:850-857.
- Bertorini TE. Neuromuscular Disorders: Treatment and Management. Elsevier Philadelphia 2011 p334.
- Finlayson S, Beeson D, Palace J. Congenital myasthenic syndrome: an update. Pract Neurol 2013; 13:80-91.
- Harper CM, Fukodome T, Engel AG. Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. Neurology 2003; 60:1710-1713.
- Peyer AK, Abicht A, Heinimann K, Sinnreich M, Fischer D. Quinine sulfate as a therapeutic option in a patient with slow channel congenital myasthenic syndrome. Neuromuscul Disord 2013; 23:571-574.
- And 1 more. Subscribe to see the full list
